Braidwell LP Sells 130,400 Shares of Sarepta Therapeutics, Inc. $SRPT

Key Points

• Braidwell LP reduced its stake in Sarepta Therapeutics by 35.7%, owning 234,500 shares worth approximately $14.97 million after selling 130,400 shares in Q1.
• Research analysts have mixed views on Sarepta, with price targets ranging from $19.00 to $50.00, and a consensus rating of "Hold".
• The company reported a 68.4% increase in quarterly revenue year-over-year, totaling $611.09 million, along with an EPS of $2.02 that beat expectations.

Braidwell LP trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 35.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 234,500 shares of the biotechnology company's stock after selling 130,400 shares during the quarter. Braidwell LP owned about 0.24% of Sarepta Therapeutics worth $14,966,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Vident Advisory LLC increased its position in Sarepta Therapeutics by 27.8% during the first quarter. Vident Advisory LLC now owns 3,748 shares of the biotechnology company's stock worth $239,000 after buying an additional 815 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $11,997,000. FORA Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $386,000. University of Wisconsin Foundation acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $1,769,000. Finally, Jump Financial LLC grew its position in shares of Sarepta Therapeutics by 218.2% in the first quarter. Jump Financial LLC now owns 5,785 shares of the biotechnology company's stock valued at $369,000 after purchasing an additional 3,967 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

SRPT traded down $0.49 during midday trading on Thursday, reaching $18.46. 4,894,439 shares of the company's stock were exchanged, compared to its average volume of 6,376,307. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -21.22 and a beta of 0.49. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $138.81. The business has a 50-day simple moving average of $17.72 and a two-hundred day simple moving average of $45.58.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.07 earnings per share. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Barclays raised Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 price target on the stock in a research report on Tuesday, July 29th. Scotiabank raised Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target on the stock in a research report on Friday, June 6th. BMO Capital Markets raised their price target on Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a research report on Tuesday, July 29th. Finally, Wolfe Research assumed coverage on Sarepta Therapeutics in a research report on Tuesday, June 17th. They issued a "peer perform" rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $43.50.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.